- Home
- SI vs LRMR Comparison
SI vs LRMR Comparison
Compare SI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | LRMR |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.3M | 316.6M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | SI | LRMR |
|---|---|---|
| Price | $14.54 | $3.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $20.60 | $16.71 |
| AVG Volume (30 Days) | 47.0K | ★ 1.1M |
| Earning Date | 02-10-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,626,000.00 | N/A |
| Revenue This Year | $48.42 | N/A |
| Revenue Next Year | $29.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 115.97 | N/A |
| 52 Week Low | $10.92 | $1.61 |
| 52 Week High | $17.94 | $5.37 |
Technical Indicators
Market Signals| Indicator | SI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.31 |
| Support Level | N/A | $3.31 |
| Resistance Level | N/A | $4.01 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 0.00 | 14.34 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.